Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
guardian 2: N8 Extension in Haemophilia A
NCT00984126Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Oct 2009
- Primary completion
- Jun 2016
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 20
01
Overview
Phase 3, open-label, single-arm trial of turoctocog alfa in hemophilia A, sponsored by Novo Nordisk. Primary endpoint: Frequency of Development of FVIII Inhibitors (Greater Than or Equal to 0.6 Bethesda Units (BU)/mL) at 90 months. Started Oct 2009; status: completed.
02
Drugs
turoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on NCT00984126.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00984126.